Effect of nitric oxide synthase (NOS) activity on Lenvatinib for unresectable hepatocellular carcinoma

JRCT ID: jRCT1030210283

Registered date:27/08/2021

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Unresectable hepatocellular carcinoma
• Date of first enrollment: 27/08/2021
• Target sample size: 100
• Study type: Observational

Outcome(s)

• Primary Outcome: Comparison of NOS activity at the time of initial administration and after administration in patients with hepatocellular carcinoma treated with lenvatinib
• Secondary Outcome: Effect of NOS activity at first dose on response rate, overall survival, progression-free survival, Time To Progression, Time to treatment failure, and incidence of adverse effects after lenvatinib treatment

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Patients with hepatocellular carcinoma who received lenvatinib between October 1, 2018 and September 30, 2020.
Patients enrolled in the "Multicenter Study of Factors Contributing to the Efficacy and Survival of Lenvatinib in Hepatocellular Carcinoma".
Patients who have arbitrarily stored serum before and after treatment.

• Exclude criteria: Patients who are considered unsuitable for participation in this study by the principal investigator and sub-investigators

Related Information

• Primary Sponsor: Hidaka Hisashi